X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clofarabine (117) 117
humans (107) 107
index medicus (106) 106
hematology (76) 76
oncology (72) 72
female (58) 58
male (58) 58
adult (50) 50
middle aged (45) 45
arabinonucleosides - administration & dosage (44) 44
treatment outcome (44) 44
adenine nucleotides - administration & dosage (43) 43
cancer (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
acute myeloid-leukemia (38) 38
aged (38) 38
chemotherapy (36) 36
leukemia, myeloid, acute - drug therapy (34) 34
transplantation (34) 34
adolescent (31) 31
recurrence (30) 30
remission induction (30) 30
acute myeloid leukemia (29) 29
arabinonucleosides - therapeutic use (29) 29
child (29) 29
young adult (29) 29
leukemia (28) 28
cytarabine (27) 27
acute lymphoblastic-leukemia (26) 26
adenine nucleotides - therapeutic use (26) 26
acute myelogenous leukemia (25) 25
adenine nucleotides - adverse effects (25) 25
arabinonucleosides - adverse effects (25) 25
pediatric-patients (25) 25
relapse (24) 24
research (24) 24
salvage therapy (24) 24
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
article (23) 23
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (23) 23
child, preschool (22) 22
stem cells (22) 22
cytarabine - administration & dosage (21) 21
antineoplastic agents (19) 19
care and treatment (19) 19
children (19) 19
antimitotic agents (18) 18
therapy (18) 18
hematology, oncology and palliative medicine (17) 17
leukemia, myeloid, acute - mortality (17) 17
aml (16) 16
antineoplastic agents - therapeutic use (16) 16
fludarabine (16) 16
myelodysplastic syndrome (16) 16
pediatrics (16) 16
salvage therapy - methods (16) 16
stem-cell transplantation (16) 16
cyclophosphamide (15) 15
hematopoietic stem cells (15) 15
nucleoside analog (15) 15
pharmacology & pharmacy (15) 15
combination (14) 14
cytarabine - adverse effects (14) 14
health aspects (14) 14
hematopoietic stem cell transplantation (14) 14
infant (14) 14
refractory (14) 14
ribonucleotide reductase (14) 14
survival analysis (14) 14
adults (13) 13
bone-marrow-transplantation (13) 13
cytosine-arabinoside (13) 13
disease-free survival (13) 13
dose-response relationship, drug (13) 13
high-dose cytarabine (13) 13
leukemia, myeloid, acute - therapy (13) 13
older patients (13) 13
prognosis (13) 13
2-chloro-9-adenine (12) 12
chronic lymphocytic-leukemia (12) 12
cladribine (12) 12
cyclophosphamide - administration & dosage (12) 12
dosage and administration (12) 12
medicine & public health (12) 12
myelodysplastic syndromes - drug therapy (12) 12
phase-ii (12) 12
retrospective studies (12) 12
abridged index medicus (11) 11
adult patients (11) 11
arabinonucleosides - pharmacology (11) 11
diseases (11) 11
drug administration schedule (11) 11
etoposide (11) 11
immunology (11) 11
survival (11) 11
survival rate (11) 11
adenine nucleotides - pharmacology (10) 10
animals (10) 10
clinical trials as topic (10) 10
clofarabine salvage therapy (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatric Blood & Cancer, ISSN 1545-5009, 03/2014, Volume 61, Issue 3, pp. 479 - 487
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2012, Volume 156, Issue 2, pp. 205 - 212
Journal Article
Leukemia Research, ISSN 0145-2126, 2015, Volume 39, Issue 12, pp. 1353 - 1359
Journal Article
Journal Article
Medicine, ISSN 0025-7974, 09/2018, Volume 97, Issue 39, p. e12102
To assess treatment response and overall survival (OS) in refractory or relapsed acute myeloid leukemia (R/R AML) patients treated by different common salvage... 
CLOFARABINE | PLUS CYTARABINE | NUCLEOSIDE ANALOGS | K562 CELLS | HOMOHARRINGTONINE | INDUCTION | chemotherapy regimen | FLUDARABINE | CLADRIBINE | TRANSPLANTATION | CLAG | ACLARUBICIN | MEDICINE, GENERAL & INTERNAL | treatment response | overall survival | refractory or relapsed acute myeloid leukemia (R/R AML) | Salvage Therapy - adverse effects | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Harringtonines - adverse effects | Male | Cytarabine - adverse effects | Harringtonines - therapeutic use | Young Adult | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Retrospective Studies | Aclarubicin - therapeutic use | Mitoxantrone - adverse effects | Mitoxantrone - therapeutic use | Aclarubicin - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Daunorubicin - therapeutic use | Etoposide - adverse effects | Vidarabine - adverse effects | Etoposide - therapeutic use | Survival Rate | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Daunorubicin - adverse effects | Leukemia, Myeloid, Acute - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cladribine - therapeutic use | Aged | Cladribine - adverse effects | Salvage Therapy - methods | Cohort Studies | Chemotherapy | Relapse | Care and treatment | Patient outcomes | Methods | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 676 - 683
Journal Article